fbpx Skip to main content

Member Spotlight

May 31, 2019

AccendoWave CEO and Co-Founder, Martha Lawrence

Biocom Kicks Off Biocom Member Spotlight and Features AccendoWave

Martha Lawrence, AccendoWave, CEO & Co-Founder


We’ve been hearing AccendoWave’s name a lot in the Biocom network recently. Can you briefly explain your technology and its application?

AccendoWave is a machine learning technology that measures and helps manage pain through full-spectrum brain analysis, where we correlate brainwaves with your perception of pain or discomfort. Our strategic partners are Samsung and AT&T and we have the largest real-time database on pain with more than 40,000 patients who have used the technology in hospitals. There are three main channels we target: hospitals, biotech/pharma, and data analytics.

We are thrilled to announce the launch of a special series where each Friday we will be turning the spotlight on one of our members who are making an impact in the life science industry. Impressive accomplishments and innovative discoveries are being made by many of our Biocom members who are pushing the boundaries of what is possible—we can’t wait to share them with you! Today we kick off our Biocom Member Spotlight series with AccendoWave!rnrnBiocom recently had the pleasure to sit down with Martha Lawrence, CEO and Co-Founder of AccendoWave; a machine learning pain measurement and pain management platform company headquartered in Los Angeles, California. Martha was fresh off the heels of Biocom’s Connected Health Advocacy Fly-In for two days of high-level meetings with senior officials in some of Washington, D.C.’s most prestigious government institutions, and had just wrapped a company presentation at Biocom’s Kaiser Day at our headquarters in San Diego. Talk about a woman and a company on the move…

Which channel would you say is your biggest target?

At this point, our largest sector is hospitals, but we are getting increasing interest from biotech/pharma. They’re interested in our technology and our ability to measure pain. So in general, there are three areas of interest for them: consumer health – pairing our technology with something they have on the consumer health side, clinical trials and the third is value-based care or outcomes – the ability to help differentiate drugs to substantiate value to different stakeholders.

What excites you most about what AccendoWave is currently doing?

We’re excited about the work that we are doing both at an individual patient level and at an institutional macro level. At a patient level, we’re helping the patient with their pain while they’re in the hospital. We provide feedback on how they’re feeling – they can see their brainwaves, the pain scale lights up and they have content that actually changes based on their brain activity. Whatever is reducing their pain, the algorithm is smart and all the content is stored in a library. That content is linked and it looks for more content that is similar and serves that back to the patient. Think of it as brainwave-controlled TV in your lap for pain.

“We’re excited about the work that we are doing both at an individual patient level and at an institutional macro level.”

Can you elaborate on some of the recent connections you’ve made within the Biocom network since joining last October?

I just returned from the Fly-In in D.C. and it was both a very meaningful experience for AccendoWave and a great first dive into the Biocom community. The trip highlighted the life sciences within California and how important they are, in terms of an industry. It was helpful for us to be able to visit with a variety of key stakeholders. We had a chance to visit with the NIH, the ONC, the FDA, with various high-level committees in Congress, as well as Congressional Representatives. It was a nice opportunity to provide visibility to some of the really innovative technology that’s coming from the California community and make sure there is a blend of understanding the technology, as well as a reimbursement path for that technology.

Can you walk us through a quick snapshot of pain data analytics?

Yes, one analysis that we think is important is night shift compared to day shift. We’re also looking at “What’s the average level of pain by department?” “Do you have a department that’s an outlier in terms of pain?” We are also doing a quantified pain analysis within each department. We use a five-point scale instead of a ten-point scale and we can provide the levels of pain by department. Those are some of the early metrics that we’re providing around pain and they vary by customer. The data metrics around pharma/biotech look different than on the data analytics side. There, it’s really around population health and precision medicine. For the first time, we have pain data and the question is, “How do we incorporate that data into the data sets that we already have?”

“For the first time, we have pain data and the question is, ‘How do we incorporate that data into the data sets that we already have?'”

What excites you most about the future of AccendoWave?

What excites us about the future is the ability to use our real-time pain database in a variety of ways for different stakeholders. We have never really had pain data available before – it is very difficult to get out of your electronic health record. Institutions just haven’t had that at both an individual level and at a macro institutional level. There are ways that data can be used to help institutions. For example, if you have a pain problem at night, you can measure your day shift versus your night shift. There are also a variety of different ways you can sort the data. From a data perspective, we are very in tune with our customers. I would tell you our hospitals are drowning in data, and they don’t need more data. What they need is actionable data and that’s our goal of providing them with actionable data around pain.